['relapsing remitting multiple sclerosis']
['alks 8700', 'dimethyl fumarate']

        Key Inclusion Criteria:

          -  Capable of understanding and complying with the protocol

          -  Has a confirmed diagnosis of RRMS

          -  Neurologically stable with no evidence of relapse within 30 days prior to
             randomization

          -  Agrees to use an acceptable method of contraception for the duration of the study and
             for 30 days after any study drug administration, or is surgically sterile or
             post-menopausal

        Key Exclusion Criteria:

          -  Have any finding(s) that would compromise the safety of the subject, affect the
             subject's ability to adhere to the protocol visit schedule or to fulfill visit
             requirements, or would make the subject unsuitable for participation in the study

          -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

          -  History of clinically significant cardiovascular, pulmonary, GI, dermatologic,
             psychiatric, neurologic (other than MS), endocrine, renal, and/or other major disease
             that would preclude participation in a clinical trial

          -  History of GI surgery (except appendectomy that occurred more than 6 months prior to
             screening

          -  History of clinically significant recurring or active gastrointestinal symptoms (eg,
             nausea, diarrhea, dyspepsia, constipation) within 3 months of screening

          -  Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month of
             screening Has a clinically significant medical condition or observed abnormality at
             screening

          -  History of a myocardial infarction, including a silent myocardial infarction or
             unstable angina

          -  History of clinically significant drug or alcohol abuse within the past year prior to
             screening

          -  Clinically significant history of suicidal ideation or suicidal behavior in the last
             12 months

          -  Subject is pregnant or breastfeeding or plans to become pregnant or begin
             breastfeeding at any point during the study and for 30 days after any study drug
             administration

          -  Prior use of Dimethyl Fumarate (DMF)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      